Primary Systemic Therapy for Operable Breast Cancer
Author Information
Author(s): E.D.C. Anderson, A.P.M. Forrest, R.A. Hawkins, T.J. Anderson, R.C.F. Leonard, U. Chetty
Primary Institution: University Department of Surgery, Royal Infirmary, Edinburgh
Hypothesis
Can primary systemic therapy improve outcomes for patients with operable breast cancer?
Conclusion
The study suggests that primary systemic therapy can lead to significant tumor regression and high survival rates in patients with operable breast cancer.
Supporting Evidence
- 39% of patients receiving endocrine therapy showed significant tumor regression.
- 72% of patients receiving cytotoxic therapy showed significant tumor regression.
- Overall survival rate at 3 years was 86%.
Takeaway
This study looked at how giving treatment before surgery can help women with large breast tumors. It found that many women had smaller tumors after treatment, which is a good sign.
Methodology
Patients with operable breast cancer received either endocrine or cytotoxic therapy, and their responses were assessed after 12 weeks.
Potential Biases
Potential selection bias in patient eligibility and treatment assignment.
Limitations
The study did not include a control group for comparison with standard treatment.
Participant Demographics
Mean age was 53.1 years; 38 were premenopausal and 50 were postmenopausal.
Statistical Information
P-Value
0.025
Confidence Interval
76-96%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website